GlassScriptPhysician profile
Amber Kaylor
NPI 1760072888
$1,522.25
in general payments reported to CMS, 2019-2025
16 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $241 · 2023: $436 · 2024: $290 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.69 | 2023-2025 | |
| Lilly USA, LLC | $203.93 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $148.75 | 2022 | |
| Novo Nordisk INC | $145.52 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceuticals, INC. | $113.18 | 2021 | |
| Shield Therapeutics INC | $98.19 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $94.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Corium, LLC | $58.85 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $51.29 | 2021-2023 | Trintellix |
| Lundbeck LLC | $22.45 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $22.28 | 2025 | Voquezna |
| Pfizer INC. | $20.63 | 2023 | |
| Astellas Pharma US INC | $18.77 | 2024 | Veozah |
| Dexcom, INC. | $16.50 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.01 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Kaylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.